February 20, 2019
EA Pharma, a gastrointestinal disease subsidiary of Eisai, said on February 19 that it has snagged development and commercialization rights in Japan for German drug maker Dr. Falk Pharma’s investigational liver disease treatment nor-ursodeoxycholic acid (norUDCA). Under the deal, EA...read more